Literature DB >> 25313347

Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score.

Richard Wyss1, Mark Lunt2, M Alan Brookhart1, Robert J Glynn3, Til Stürmer1.   

Abstract

The prognostic score, or disease risk score (DRS), is a summary score that is used to control for confounding in non-experimental studies. While the DRS has been shown to effectively control for measured confounders, unmeasured confounding continues to be a fundamental obstacle in non-experimental research. Both theory and simulations have shown that in the presence of unmeasured confounding, controlling for variables that affect treatment (both instrumental variables and measured confounders) amplifies the bias caused by unmeasured confounders. In this paper, we use causal diagrams and path analysis to review and illustrate the process of bias amplification. We show that traditional estimation strategies for the DRS do not avoid bias amplification when controlling for predictors of treatment. We then discuss estimation strategies for the DRS that can potentially reduce bias amplification that is caused by controlling both instrumental variables and measured confounders. We show that under certain assumptions, estimating the DRS in populations outside the defined study cohort where treatment has not been introduced, or in outside populations with reduced treatment prevalence can control for the confounding effects of measured confounders while at the same time reduce bias amplification.

Entities:  

Year:  2014        PMID: 25313347      PMCID: PMC4193945          DOI: 10.1515/jci-2014-0009

Source DB:  PubMed          Journal:  J Causal Inference        ISSN: 2193-3685


  19 in total

1.  Invited commentary: understanding bias amplification.

Authors:  Judea Pearl
Journal:  Am J Epidemiol       Date:  2011-10-27       Impact factor: 4.897

2.  Effects of adjusting for instrumental variables on bias and precision of effect estimates.

Authors:  Jessica A Myers; Jeremy A Rassen; Joshua J Gagne; Krista F Huybrechts; Sebastian Schneeweiss; Kenneth J Rothman; Marshall M Joffe; Robert J Glynn
Journal:  Am J Epidemiol       Date:  2011-10-24       Impact factor: 4.897

3.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

4.  Confounding control in healthcare database research: challenges and potential approaches.

Authors:  M Alan Brookhart; Til Stürmer; Robert J Glynn; Jeremy Rassen; Sebastian Schneeweiss
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

5.  On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study.

Authors:  Finbarr P Leacy; Elizabeth A Stuart
Journal:  Stat Med       Date:  2013-10-22       Impact factor: 2.373

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.

Authors:  Fausto G Patino; Jeroan Allison; Jason Olivieri; Amy Mudano; Lucia Juarez; Sharina Person; Ted R Mikuls; Larry Moreland; Stacey H Kovac; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2003-06-15

8.  Confounder summary scores when comparing the effects of multiple drug exposures.

Authors:  Suzanne M Cadarette; Joshua J Gagne; Daniel H Solomon; Jeffrey N Katz; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-01       Impact factor: 2.890

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  Propensity score calibration in the absence of surrogacy.

Authors:  Mark Lunt; Robert J Glynn; Kenneth J Rothman; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2012-04-24       Impact factor: 4.897

View more
  4 in total

1.  The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.

Authors:  Richard Wyss; Ben B Hansen; Alan R Ellis; Joshua J Gagne; Rishi J Desai; Robert J Glynn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2017-05-01       Impact factor: 4.897

2.  Matching on the disease risk score in comparative effectiveness research of new treatments.

Authors:  Richard Wyss; Alan R Ellis; M Alan Brookhart; Michele Jonsson Funk; Cynthia J Girman; Ross J Simpson; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-06-25       Impact factor: 2.890

3.  Bespoke Instruments: A new tool for addressing unmeasured confounders.

Authors:  David B Richardson; Eric J Tchetgen Tchetgen
Journal:  Am J Epidemiol       Date:  2022-03-24       Impact factor: 5.363

4.  Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches.

Authors:  Justin Bohn; Sebastian Schneeweiss; Robert J Glynn; Sengwee Toh; Richard Wyss; Rishi Desai; Joshua J Gagne
Journal:  EGEMS (Wash DC)       Date:  2019-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.